MBRX — Moleculin Biotech, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-06-02.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-03 | Foster Jonathan P. Chief Financial Officer | Open-market purchase | 293.3K | — | — |
| 2026-08-03 | PICKER DONALD H Chief Science Officer | Open-market purchase | 173.3K | — | — |
| 2026-08-03 | KLEMP WALTER V CEO and President | Open-market purchase | 533.3K | — | — |
| 2026-06-22 | KLEMP WALTER V CEO and President | Shares withheld for tax | 88 | 3.12 | 275 |
| 2026-06-22 | Foster Jonathan P. Chief Financial Officer | Shares withheld for tax | 41 | 3.12 | 128 |
| 2026-06-22 | PICKER DONALD H Chief Science Officer | Shares withheld for tax | 21 | 3.12 | 66 |
| 2026-06-22 | Foster Jonathan P. Chief Financial Officer | Option exercise | 174 | — | — |
| 2026-06-22 | KLEMP WALTER V CEO and President | Option exercise | 360 | — | — |
| 2026-06-22 | PICKER DONALD H Chief Science Officer | Option exercise | 71 | — | — |
| 2026-06-20 | KLEMP WALTER V CEO and President | Shares withheld for tax | 37 | 2.88 | 107 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| SABBY MANAGEMENT, LLC | 171.8K | 75.0K |
| GEODE CAPITAL MANAGEMENT, LLC | 74.0K | 32.3K |
| VANGUARD CAPITAL MANAGEMENT LLC | 31.8K | 13.9K |
| VANGUARD FIDUCIARY TRUST CO | 13.9K | 6.1K |
| Rockefeller Capital Management L.P. | 10.1K | 4.4K |
| UBS Group AG | 7.8K | 3.4K |
| Tower Research Capital LLC (TRC) | 4.2K | 1.8K |
| BlackRock, Inc. | 1.1K | 491 |
| EFG International AG | 994 | 434 |
| Pinnacle Wealth Planning Services, Inc. | 643 | 281 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| PRE 14A | 2026-08-14 | 2026-10-09 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-10 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-06 | — | on EDGAR ↗ |
| 4 | 2026-08-05 | 2026-08-03 | on EDGAR ↗ |
| 4 | 2026-08-05 | 2026-08-03 | on EDGAR ↗ |
| 4 | 2026-08-05 | 2026-08-03 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Moleculin Biotech, Inc. (MBRX) filed form 8-K · 2026-08-14 · SEC EDGAR
Ask the AI about MBRX
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →